#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Clinical study ODYSSEY OUTCOMES


Authors: J. Murín 1;  J. Špinar 2
Authors‘ workplace: I. interná klinika LF UK a UN Bratislava 2 Interní kardiologická klinika LF MU a FN Brno 1
Published in: Kardiol Rev Int Med 2018, 20(2): 131-136

Overview

Patients suffering from acute coronary syndrome (ACS) have a very high cardiovascular (CV) risk of morbidity and mortality even with an optimal treatment of ACS and optimal secondary prevention treatment afterwards. A more intensive treatment of dyslipidaemia, with further reduction of serum LDL-cholesterol (LDL-c) levels, should improve prognosis of these patients – such was the hypothesis of this study with alirocumab (PCSK9 inhibitor) treatment vs. placebo treat­ment. There were 18,924 patients in this study, randomized for the above-mentioned treatment in the time period of 1–12 months after ACS. In the active arm treatment there was a further reduction of serum LDL-c level (from 2.62 to 1.37 mmol/l, reduction of 54.7%). This serum LDL-c reduction contributed to a reduction of the primary end-point (coronary mortality/nonfatal myocardial infarction and stroke/hospitalization for unstable angina pectoris) of 15% (significantly – S), and also to an improvement of the components of this end-point and 15% reduction of all-cause mortality (S). The best benefit was achieved in the subgroup of patients with the highest serum level of LDL-c ≥ 2.6 mmol/l – the primary end-point was reduced by 24% (S) and CV mortality by 31% (S). The treatment was safe. The output of this study is a great reduction of CV events (mortality, nonfatal myocardial infarctions and strokes, unstable angina pectoris) in patients with an ACS treated by alirocumab – all patients had an excellent standard treatment of the disease, including strong and high doses of stat­ins. Patients with the highest basal serum LDL-c levels (≥ 2.6 mmol/l) profited most.

Key words:

hypercholesterolemia – alirocumab – cardiovascular events


Sources

1. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367(22): 2089– 2099. doi: 10.1056/ NEJMoa1206797.

2. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:  the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711– 1718.

3. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lower­ing with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495– 1504. doi: 10.1056/ NEJMoa040583.

4. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and underrecognized: the late concequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31(22): 2755– 2764. doi: 10.1093/ eurheartj/ ehq326.

5. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart dis­ease continuous and graded? Find­ing in 356,222 primary screenees of the Multiple Risk Factor Intervention. Trial (MRFIT). JAMA 1986; 256(20): 2823– 2828.

6. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lower­ing of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670– 1681. doi: 10.1016/ S0140-6736(10)61350-5.

7. Wiviott SD, Cannon CP, Morrow DA et al. Can low-density lipoprotein be too low? The safety and efficacy of achiev­ing very low low-density lipoprotein with intensive statin ther­apy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46(8): 1411– 1416. 10.1016/ j.jacc.2005.04.064.

8. Karalis DG, Victor B, Ahedor I et al. Use of lipid--lower­ing medications and the likelihood of ochiev­ing optimal LDL-cholesterol goals in coronary artery dis­ease patients. Cholesterol 2012; 2012: 861924. doi: 10.1155/ 2012/ 861924.

9. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug ther­apies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 121– 137. doi: 10.1097/ HJR.0b013e3283294b1d.

10. Do RQ, Vogel RA, Schwartz GG. PCSK9 inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 2013; 15(3): 345. doi: 10.1007/ s11886-012-0345-z.

11. Cohen JC, Boerwinkle E, Mosley TH Jr et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart dis­ease. N Engl J Med 2006; 354(12): 1264– 1272.

12. Naoumova RP, Tosi I, Patel D et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25(12): 2654– 2660. doi: 10.1161/ 01.ATV.0000190668.94752.ab.

13. Welder G, Zineh I, Pacanowski MA et al. High-dose atorvastatin causes a rapid sustained in­crease in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51(9): 2714– 2721. doi: 10.1194/ jlr.M008144.

14. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monodonal antibody to PCSK9 on LDL choles­terol. N Engl J Med 2012; 366(12): 1108– 1118. doi: 10.1056/ NEJMoa1105803.

15. McKenney JM, Koren MU, Kereiakes DJ et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiv­ing ongo­ing stable atorvastatin ther­apy. J Am Coll Cardiol 2012; 59(25): 2344– 2353. doi: 10.1016/ j.jacc.2012.03.007.

16. Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe ther­apy: a phase 2 randomised con­trolled trial. Lancet 2012; 380(9836): 29– 36. doi: 10.1016/ S0140-6736(12)60771-5.

17. Roth EM, McKenney JM, Hanotin C et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367(20): 1891– 1900. doi: 10.1056/ NEJMoa1201832.

18. Martin SS, Blaha MJ, Elshazly MB et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013; 62(8): 732– 739. doi: 10.1016/ j.jacc.2013.01.079.

19. Dolan P. Model­ing valuations for EuroQol health states. Med Care 1997; 35(11): 1095– 1108.

20. Schwartz GG, Bessac L, Berdan LG et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes follow­ing acute coronary syndromes:  rationale and design of the ODDYSSEY OUTCOMES trial. Am Heart J 2014; 168(5): 682– 689.e1. doi: 10.1016/ j.ahj.2014.07.028.

21. Steg PG, Schwartz GG, Szarek M et al. The ODYS­SEY OUTCOMES Trial: Topline results. Alirocumab in patients after acute coronary syndrome. American College of Cardiology –  67th Scientific Sessions, 2018, Orlando USA. Available at: https:/ / accscientificsession.acc.org/ .

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#